Compare HRMY & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | DEI |
|---|---|---|
| Founded | 2017 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2020 | 2006 |
| Metric | HRMY | DEI |
|---|---|---|
| Price | $38.12 | $11.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 8 |
| Target Price | ★ $44.11 | $12.94 |
| AVG Volume (30 Days) | 881.8K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 7.06% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | $868,453,000.00 | ★ $1,003,982,000.00 |
| Revenue This Year | $19.75 | $1.70 |
| Revenue Next Year | $12.88 | $2.35 |
| P/E Ratio | $20.92 | ★ N/A |
| Revenue Growth | ★ 21.51 | 1.77 |
| 52 Week Low | $25.52 | $9.04 |
| 52 Week High | $40.87 | $16.94 |
| Indicator | HRMY | DEI |
|---|---|---|
| Relative Strength Index (RSI) | 56.72 | 46.03 |
| Support Level | $34.87 | $11.14 |
| Resistance Level | $39.24 | $12.68 |
| Average True Range (ATR) | 1.33 | 0.39 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 66.49 | 40.69 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.